Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N. Porfir'eva
RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine
Medicine
Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pet-Adapted Nivolumab +/- Ice as Initial Salvage Therapy in Relapsed/Refractory Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Response-Adapted Treatment With Nivolumab and Brentuximab Vedotin in Young Patients With Relapsed/Refractory Classical Hodgkin Lymphoma: Checkmate 744 Subgroup Analyses
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Nivolumab for Relapsed/Refractory Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure – Polish Lymphoma Research Group Real-Life Experience
Acta Haematologica Polonica
Oncology
Hematology
Major Clinical Response to Nivolumab in Relapsed/Refractory Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation
Bone Marrow Transplantation
Transplantation
Hematology
Treatment of Refractory and Relapsed Hodgkin's Lymphoma: Facts and Perspectives
Haematologica
Hematology
Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Prognostic Value of Comorbidity for Auto-SCT Eligibility and Outcome in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Bone Marrow Transplantation
Transplantation
Hematology
